Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Swiss National Bank

Swiss National Bank lessened its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 2.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 653,500 shares of the medical equipment provider's stock after selling 18,800 shares during the quarter. Swiss National Bank owned about 0.31% of Zimmer Biomet worth $79,531,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Schechter Investment Advisors LLC raised its stake in Zimmer Biomet by 21.6% during the 3rd quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider's stock valued at $476,000 after buying an additional 752 shares during the last quarter. Atria Wealth Solutions Inc. boosted its position in Zimmer Biomet by 5.9% in the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider's stock worth $2,312,000 after purchasing an additional 1,144 shares during the last quarter. International Assets Investment Management LLC grew its stake in shares of Zimmer Biomet by 11,244.9% during the 4th quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider's stock valued at $8,146,000 after purchasing an additional 66,345 shares during the period. Amalgamated Bank increased its position in shares of Zimmer Biomet by 3.0% during the 3rd quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider's stock valued at $6,303,000 after purchasing an additional 1,631 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its stake in shares of Zimmer Biomet by 37.5% in the 4th quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider's stock worth $18,981,000 after purchasing an additional 42,539 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Insider Activity

In other news, VP Chad F. Phipps sold 26,156 shares of the firm's stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total value of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares of the company's stock, valued at approximately $5,677,929.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.95% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. Barclays upped their target price on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an "underweight" rating in a report on Monday, February 12th. Royal Bank of Canada restated an "outperform" rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 9th. Evercore ISI lifted their target price on Zimmer Biomet from $125.00 to $130.00 and gave the company an "in-line" rating in a research report on Thursday, April 4th. JPMorgan Chase & Co. upped their price target on Zimmer Biomet from $115.00 to $125.00 and gave the stock a "neutral" rating in a research report on Friday, February 9th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Thursday. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Zimmer Biomet currently has an average rating of "Hold" and a consensus price target of $135.40.

Zimmer Biomet Price Performance

ZBH traded up $3.20 during trading on Friday, hitting $121.66. 1,847,585 shares of the company traded hands, compared to its average volume of 1,304,580. The company has a market cap of $25.00 billion, a PE ratio of 26.33, a P/E/G ratio of 2.23 and a beta of 1.03. Zimmer Biomet Holdings, Inc. has a 1 year low of $102.00 and a 1 year high of $147.50. The company has a current ratio of 1.66, a quick ratio of 0.78 and a debt-to-equity ratio of 0.38. The stock's 50-day simple moving average is $125.30 and its two-hundred day simple moving average is $120.21.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.87 by $0.07. The firm had revenue of $1.89 billion for the quarter, compared to analysts' expectations of $1.87 billion. Zimmer Biomet had a return on equity of 12.70% and a net margin of 12.93%. The business's revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.89 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.1 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th were issued a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.79%. Zimmer Biomet's dividend payout ratio (DPR) is presently 20.78%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.